Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 10/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27324363 | 1.00 | PTGS1 (0.50) | PTGS1SLC7A11SLC22A6ENPEPANPEP | |
| SCHEMBL7979726 | 0.80 | PTGS1 (0.50) | PTGS1SLC7A11SLC22A6ENPEPANPEP | |
| Cysteine SCHEMBL431234 | 0.75 | PTGS1 (0.80) | PTGS1SLC7A11ENPEPANPEPPMP22 | |
| Cysteine SCHEMBL11127428 | 0.75 | PTGS1 (0.80) | PTGS1SLC7A11ENPEPANPEPPMP22 | |
| Cysteine SCHEMBL11127430 | 0.75 | PTGS1 (0.80) | PTGS1SLC7A11ENPEPANPEPPMP22 | |
| SCHEMBL2036153 | 0.75 | SLC22A6 (0.36) | SLC22A6PMP22 | |
| Cysteine SCHEMBL431233 | 0.75 | PTGS1 (0.80) | PTGS1SLC7A11ENPEPANPEPPMP22 | |
| Cysteine SCHEMBL7728523 | 0.73 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPANPEPPMP22 | |
| Cysteine SCHEMBL9490762 | 0.73 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPANPEPPMP22 | |
| Cysteine SCHEMBL8817362 | 0.73 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPANPEPPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577901-A | Urine metabolism marker combination for distinguishing benign kidney diseases from kidney cancers and application thereof | 哈尔滨脉图精准技术有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-04-30 | — | — | US | disclosed |
| EP-4732845-A2 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | Novartis AG (CH) | 2026-04-29 | — | — | EP | disclosed |
| CN-121577901-A | Urine metabolism marker combination for distinguishing benign kidney diseases from kidney cancers and application thereof | 哈尔滨脉图精准技术有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2026-01-20 | — | — | US | disclosed |
| WO-2025099157-A1 | ABSOLUTE QUANTIFICATION OF ISOFORMS OF A PROTEIN OF INTEREST BY INTERNAL CALIBRATION BASED ON A TOP-DOWN LC-MS APPROACH | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-15 | — | — | WO | disclosed |
| US-20250034241-A1 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| EP-4389143-A2 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | Novartis AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024088066-A1 | SARCOPENIA DIAGNOSIS MARKER AND USE THEREOF | 生物岛实验室 | 2024-05-02 | — | — | WO | disclosed |
| US-20220315650-A1 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| CN-108883345-B | Method for protein purification | UCB生物制药私人有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220249644-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2022-08-11 | — | — | US | disclosed |
| US-11292833-B2 | Selective reduction of cysteine residues in IL-17 antibodies | NOVARTIS AG (CH) | 2022-04-05 | — | — | US | disclosed |
| CN-1029976-C | Process for reducing methionine sulfoxide residues | LILLY CO ELI (US) | 1995-10-11 | — | — | CN | disclosed |
| CN-1031538-A | The method of reducing methionine sulfoxide residues | LILLY CO ELI (US) | 1989-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | SCN8A, SCN9A, VIP | PTGS1 3465/4885SLC7A11 762/4885SLC22A6 780/4885 |
| US-11292833-B2 | Selective reduction of cysteine residues in IL-17 antibodies | IL17A, IL23R, IL15RA | PTGS1 1073/4885SLC7A11 588/4885SLC22A6 1412/4885 |
| US-20250034241-A1 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | IL17A, IL23R, IL15RA | PTGS1 1073/4885SLC7A11 588/4885SLC22A6 1412/4885 |
| US-20220315650-A1 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | IL17A, IL23R, IL15RA | PTGS1 1073/4885SLC7A11 588/4885SLC22A6 1412/4885 |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VIP, MLEC, SEC16A | PTGS1 4430/4885SLC7A11 601/4885SLC22A6 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.